Subcutaneous Testosterone Absorption is Comparable to Intramuscular Administration
Both subcutaneous (SC) and intramuscular (IM) routes of testosterone depot injections achieve therapeutic testosterone levels effectively, with SC administration demonstrating equivalent or superior pharmacokinetic profiles while offering practical advantages for self-administration.
Key Pharmacokinetic Findings
The absorption and bioavailability of testosterone depot preparations are not significantly impaired by subcutaneous administration compared to the traditional intramuscular route. Multiple recent studies demonstrate:
SC testosterone cypionate and enanthate achieve normal male-range testosterone levels at comparable or slightly lower doses than IM 1, 2, 3. In a 2023 prospective study of transgender adolescents, trough testosterone levels were equivalent between SC and IM groups by 6 months, though IM showed higher peak levels at 3 months 1.
Dose proportionality is maintained with SC administration. A phase II pharmacokinetic study found that SC testosterone enanthate (50-100 mg weekly) demonstrated steady, dose-proportional exposure with mean steady-state concentrations of 422.4 ng/dL (50 mg) and 895.5 ng/dL (100 mg) 4.
SC injections may require 5-10% lower doses to achieve equivalent therapeutic levels. A 2022 comparative study showed SC testosterone enanthate 100 mg weekly achieved similar trough testosterone levels to IM testosterone cypionate 100 mg weekly, with both cohorts reaching therapeutic ranges (536.4 ng/dL IM vs 552.8 ng/dL SC) 2.
Absorption Characteristics and Clinical Implications
The subcutaneous route offers distinct pharmacokinetic advantages:
More stable testosterone levels: SC administration produces less dramatic peak-to-trough fluctuations compared to IM injections 5. This is clinically relevant because the guideline literature notes that IM testosterone injections are associated with "fluctuating serum testosterone levels with peaks and valleys" as a primary disadvantage 5. Some evidence suggests these supraphysiological peaks with IM may be associated with greater cardiovascular risk, though this remains controversial 5.
Effective across body compositions: SC testosterone therapy demonstrates efficacy across a wide BMI range (19.0-49.9 kg/m²), indicating that subcutaneous fat does not significantly impair absorption 3.
Lymphatic vs. direct vascular absorption: While the evidence focuses on ester formulations (cypionate/enanthate), the absorption mechanism differs from oral testosterone undecanoate, which utilizes lymphatic transport. SC testosterone esters are absorbed from the lipid depot into systemic circulation, similar to IM but with potentially more gradual release 6, 7.
Safety Profile Comparison
SC administration demonstrates a potentially superior safety profile:
Lower estradiol conversion: SC testosterone enanthate was independently associated with significantly lower post-therapy estradiol levels compared to IM testosterone cypionate (p<0.001) 2. This likely reflects reduced aromatase activity from avoiding supraphysiological peaks.
Lower hematocrit elevation: SC was independently associated with lower post-therapy hematocrit (p<0.001) 2, an important consideration given that guidelines recommend stopping therapy if hematocrit exceeds 54% 8, 9.
Minimal injection site reactions: Only 12-14% of patients experience mild, transient local reactions with SC administration 1, 3, comparable to or better than IM tolerability.
Practical Administration Considerations
Self-administration is significantly easier with SC injections:
- 92% of adolescent patients were successfully self-injecting SC testosterone by 3 months 1
- Among 22 patients who switched from IM to SC, all expressed mild (n=2) or marked (n=20) preference for SC; none preferred IM 3
- SC injections use shorter needles (5/8-inch, 27-gauge) compared to IM (typically 1-1.5 inch) 4, reducing discomfort and technical difficulty
Dosing guidance: Start with 50-100 mg weekly SC (testosterone cypionate or enanthate), adjusting based on mid-cycle trough levels targeting 400-700 ng/dL 1, 2, 3. This is comparable to or slightly lower than typical IM dosing of 100-200 mg every 2 weeks 5, 6.
Important Caveats
- FDA labeling for testosterone cypionate specifies IM use only 6, though off-label SC use is increasingly common and supported by clinical evidence
- Testosterone undecanoate (long-acting) must be given IM only due to risk of pulmonary oil microembolism 5
- Monitoring remains identical: Check testosterone levels midway between injections for both routes, targeting mid-normal range (500-600 ng/dL) 5
- Most published evidence involves weekly dosing for SC rather than the every-2-week IM schedule, which may contribute to more stable levels
The evidence consistently demonstrates that SC testosterone depot administration achieves therapeutic absorption equivalent to IM, with practical and potentially safety advantages that make it a preferred option for many patients requiring testosterone replacement therapy.